Aortic valve stenosis (AS) is the most prevalent valvular heart disease of the elderly population in the developed world, and the disease burden is estimated to increase from 2.5 million in 2000 to 4.5 million in 2030. Comorbidities like hypertension, type 2 diabetes mellitus, dyslipidemia, chronic kidney disease, COPD, chronic inflammatory diseases, and anemia are highly prevalent in this population. They not only influence the clinical course of AS and its prognosis, but affect therapeutic success.
Fibrosis and calcification are deemed the hallmarks of disease progression and a strong independent prognostic marker for adverse events in patients with asymptomatic aortic valve stenosis. Currently, no therapeutic medication exists to halt or even slow AS progression. Given the increasing number of elderly patients with many comorbidities, there is an urgent need for a better understanding of how these disease states influence the mechanism of AS initiation and progression and the underlying pathologies like fibrosis and calcification.
The aim of this Research Topic is to gather contributions from interdisciplinary scientists working in basic, translational and clinical research exploring the interplay between aortic stenosis pathogenesis and co-morbid states, with mutual interests in elucidating the pathological molecular mechanisms, risk factors and therapeutic options to discover new mechanistic and clinical understanding of AS and comorbidities. We welcome articles uncovering new insights from bench to bedside.
This Research Topic is intended to highlight multi-disciplinary approaches, stimulate new ideas, entice more researchers to join the field, and move forward this exciting and highly significant research field. Original research, methodology, review and mini review articles are welcomed.
Aortic valve stenosis (AS) is the most prevalent valvular heart disease of the elderly population in the developed world, and the disease burden is estimated to increase from 2.5 million in 2000 to 4.5 million in 2030. Comorbidities like hypertension, type 2 diabetes mellitus, dyslipidemia, chronic kidney disease, COPD, chronic inflammatory diseases, and anemia are highly prevalent in this population. They not only influence the clinical course of AS and its prognosis, but affect therapeutic success.
Fibrosis and calcification are deemed the hallmarks of disease progression and a strong independent prognostic marker for adverse events in patients with asymptomatic aortic valve stenosis. Currently, no therapeutic medication exists to halt or even slow AS progression. Given the increasing number of elderly patients with many comorbidities, there is an urgent need for a better understanding of how these disease states influence the mechanism of AS initiation and progression and the underlying pathologies like fibrosis and calcification.
The aim of this Research Topic is to gather contributions from interdisciplinary scientists working in basic, translational and clinical research exploring the interplay between aortic stenosis pathogenesis and co-morbid states, with mutual interests in elucidating the pathological molecular mechanisms, risk factors and therapeutic options to discover new mechanistic and clinical understanding of AS and comorbidities. We welcome articles uncovering new insights from bench to bedside.
This Research Topic is intended to highlight multi-disciplinary approaches, stimulate new ideas, entice more researchers to join the field, and move forward this exciting and highly significant research field. Original research, methodology, review and mini review articles are welcomed.
